Market Access News | pharmaphorum

News

NICE backs Biogen's Vumerity for multiple sclerosis

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the d

News

UK grants early access to Novartis' prostate cancer radiolig...

The UK regulator has said eligible patients with prostate cancer will get early access to a radioligand therapy developed by Novartis' Advanced Accelerator Applications (AAA) subsidiary wh

News

NICE verdict on Trodelvy threatens unequal access to drug in...

In draft guidance, NICE has said it cannot recommend Gilead Sciences' Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the drug via the NHS in the UK.

News

Fake Dictionary, Dictionary definition of the word Schizophrenia.

BioXcel gets first approval for agitation drug Igalmi

BioXcel Therapeutics has claimed its first product approval, getting a green light from the FDA for Igalmi as a treatment for agitation in people with schizophrenia or bipolar disorder.

News

NICE reverses stance on Merck's Bavencio for bladder cancer

Last year, NICE said that Merck KGaA/Pfizer's Bavencio was too expensive for routine in NHS use as a first-line maintenance treatment for bladder cancer, even though the drug is the only ca

News

abstract shapes, bone structure, 3d render, bone

NICE ends UK access disparity to osteoporosis drug Evenity

NICE has reversed its stance on UCB and Amgen's severe osteoporosis therapy Evenity, saying out can be prescribed on the NHS for women with the disease in England and Wales who are at high

NICE backs Biogen's Vumerity for multiple sclerosis

UK grants early access to Novartis' prostate cancer radiolig...

NICE verdict on Trodelvy threatens unequal access to drug in...

BioXcel gets first approval for agitation drug Igalmi

NICE reverses stance on Merck's Bavencio for bladder cancer

NICE ends UK access disparity to osteoporosis drug Evenity

Adcomm backs Replimune melanoma drug, despite data concern

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks